Oramed Pharmaceuticals, Inc. (ORMP) Stock: Do Analysts Think You Should Accumulate?

Wall Street is positive on Oramed Pharmaceuticals, Inc. (ORMP). On average, analysts give ORMP a Hold rating. The average price target is $10.2, which means analysts expect the stock to rise by 365.75% over the next twelve months. That average ranking earns ORMP an Analyst Rating of 6, which is better than 6% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating ORMP a Hold today. Find out what this means to you and get the rest of the rankings on ORMP!

See Full ORMP Report

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Oramed Pharmaceuticals, Inc. Stock Today?

Oramed Pharmaceuticals, Inc. (ORMP) stock is higher by 0.69% while the S&P 500 has fallen -0.34% as of 12:19 PM on Friday, Mar 24. ORMP is higher by $0.01 from the previous closing price of $2.17 on volume of 92,090 shares. Over the past year the S&P 500 is down -12.94% while ORMP has fallen -77.23%. ORMP lost -$0.94 per share the over the last 12 months. Click Here to get the full Stock Report for Oramed Pharmaceuticals, Inc. stock.